A new application notebook contains many examples for GPC/SEC analysis for a broad range of polymers more
To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Polymer-based chromatographic resins featuring high mechanical and chemical stability and high protein binding capacities can help to increase the throughput and robustness of biopharmaceutical manufacturing processes.
Advances in genetic engineering and cell culture technology have raised upstream productivity in the production of recombinant proteins. Increased titres of up to 10 g/l stress the need for highly efficient and robust downstream processes (DSP). Most industrial bioprocess development groups apply generic DSP platforms that are designed to purify various candidates of the same class of proteins applying the same process design (1). Besides various filtration and virus inactivation steps, they usually involve two or three chromatographic unit operations with orthogonal separation modes. The use of high capacity chromatographic resins can help to overcome the DSP bottleneck by increasing process throughput and robustness. High sample amounts can be loaded and higher velocities applied without changing existing columns and other hardware.
Finding the best conditions for each chromatographic unit operation is of critical importance to establish a robust and efficient biopharmaceutical manufacturing process at large scale. Today the Design of Experiments (DoE) methodology and high-throughput screening (HTS) tools support efficient resin screening and method development. Applying these technologies also contributes to a better process understanding by increasing ‘prior knowledge’. This is mandatory when following the Quality by Design (QbD) approach to establish robust and validated platforms.
Monoclonal antibodies (mAbs) represent the fastest growing segment of the biopharmaceutical industry. A variety of preparative modes of chromatography have been employed for the large-scale purification of mAbs. Most schemes involve the use of protein A affinity chromatography in the capture step, exploiting the specific interactions that take place between the Fc regions of the monoclonals and immobilised protein A, a cell wall component of Staphylococcus aureus. Today, recombinant protein A ligands are used for protein A affinity resin production. Protein A affinity chromatography is well established and highly specific to mAbs. More than 95 per cent purity can be achieved in a protein A capture step. In a typical three-step mAb process, protein A chromatography is usually combined with other modes of chromatography – such as cation exchange, anion exchange or hydrophobic interaction (HIC) – to achieve pharmaceutically acceptable purity levels.
Other strategies are focusing either on reducing the number of chromatographic unit operations to a twostep process, or on developing non-protein A platforms. Eliminating a protein A step would overcome the known drawbacks of protein A chromatography such as high resin costs, protein A leaching and the formation of aggregates due to the acidic conditions needed for elution. Recently Lain et al evaluated the use of cation exchange chromatography as a mAb capture step to replace the protein A step (2). They developed a high capacity capture step for mAbs based on Toyopearl GigaCap S-650M.
In 2009, the CMC Biotech Working Group published the A-MAb Case Study, summarising the joint efforts of several large biopharm manufacturers in exemplifying a QbD approach to monoclonal antibody product development (3). A-Mab – a humanised IgG1 monoclonal antibody – was used to follow typical groups or sequences of activities that occur in the development of a monoclonal antibody including upstream and downstream processing.
A broad range of commercial chromatographic resins can be applied in large-scale mAb purification. Base particles range from soft agarose based matrices to porous glass and more rigid polymer and silica-based matrices. Common processes often combine resins of various suppliers in order to achieve maximum performance for each single step. Besides binding capacity, purity, robustness towards sanitisation and cleaning-in-place, the mechanical properties of the resin also have to be taken into account when selecting the chromatographic resin for a specific step. The rigidity of the resin influences both the ease of column packing and the bed stability in large-scale industrial columns at high velocities.
Toyopearl® resins are based on a rigid, cross-linked polymethacrylate particle. The high mechanical stability pays off in excellent pressure flow characteristics and straightforward column packing. Now, that the first Toyopearl based protein A process resin – Toyopearl AF-rProtein A-650F – is being introduced, a complete mAb purification platform based on Toyopearl can be established.
A generic mAb process assumes that a pre-defined purification template works for all monoclonals. However, physicochemical differences among mAbs require a flexible platform approach. The overall scheme of the downstream process and the limits of operating conditions can be pre-defined, but individual conditions have to be adapted to the specific target mAb. HTS and DoE are powerful tools when defining the design space of downstream processes and considerably speed up parameter scouting.
The results of the CMC study can be used to set up a mAb purification platform based on polymeric high capacity resins. HTS techniques and the DoE methodology were applied to evaluate chromatographic steps for mAb purification. Various resins and method parameters for the protein A affinity step and subsequent ion exchange steps were evaluated. Robotic platforms for parallel microscale chromatography substantially facilitate the screening of chromatographic resins and support a fast optimisation of method parameters (4); they process small screening columns in 96-well plate format in a few hours. Today, high-throughput systems complement or even replace the tedious and sample consuming columnbased screening in many industrial process development groups.
Figure 1: Breakthrough curves for hIgG loading (polyclonal, 10 mg/ml) Typical DBC at 10% breakthrough: 33 mg/mL @ 60 cm/hr (5 min residence time) - 24 mg/mL @ 200 cm/hr (1.5 min residence time) Column: 5 mm ID x 5 cm L Mobile phase: 20 mM sodium phosphate buffer pH 7.2 containing 150 mM NaCl Sample conc.: 10 mg/mL Residence time: 1.5, 2.0, 2.5, 3.0, 4.0, 5.0 min
Toyopearl AF-rProtein A-650F is an attractive candidate to improve the efficiency of a protein A based mAb capture step because it retains its high dynamic IgG binding capacity at a broad range of velocities and also when loaded with high titre feedstocks (see Figure 1). Its recombinant protein A derived ligand is attached to the rigid base matrix by multiple stable bonds resulting in low ligand leaching and high stability towards alkaline clean-in-place (CIP) conditions. Different protein A affinity resins, including the Toyopearl AF-rProtein A-650F, packed in MediaScout® MiniColumns (Atoll GmbH, Weingarten, Germany) were tested by varying the binding buffer pH, the sample load and the residence time.
|Toyopearl AF-rProtein A||200||5||3.9||100||19.2|
|Competitive rProtein A resin||200||5||3.9||100||59.7|
|Toyopearl AF-rProtein A||200||5||3.9||250||9.8|
|Competitive rProtein A resin||200||5||3.9||250||30.5|
|Toyopearl AF-rProtein A||200||25||3.9||250||47.3|
|Competitive rProtein A resin||200||25||3.9||250||629.6|
Effect of residence time on the CHO host cell protein (HCP) removal for two alkali-stable rProtein A resins: Toyopearl AF-rProtein A-650F and a competitive agarose-based resin. HCP content detected by ELISA (Cygnus Technologies). Data kindly provided by U. Breuninger, University of Applied Science Esslingen.
In order to simulate a real feedstock sample, a pure monoclonal antibody (IgG1) was spiked into a Chinese hamster ovary (CHO) cell lysate. Purity and recovery of the antibody in the eluate were monitored. The purity of the antibody fraction was tested by measuring the amount of CHO host cell proteins (HCP), and the amount of leached protein A by immunoassays. Table 1 shows the HCP removal when varying sample load and/or flow rate (residence time) at fixed bed volume and pH. Fractions purified by the Toyopearl AF-rProtein A-650F showed a lower amount of remaining host cell proteins under all conditions tested when compared to those purified by a widely used competitive rProtein A resin providing a similar IgG binding capacity.
Figure 2: Influence of binding buffer pH and elution buffer ionic strength on the CHO protein content of the mAb fraction purified by cation exchange chromatography on Toyopearl GigaCap CM-650M.
The reduction of CHO proteins (CHOP) was also evaluated for a cation exchange step by varying the parameters protein load and pH, as well as ionic strength of binding and/or elution buffer in a DoE approach. At low pH of the binding buffer, the ionic strength of the elution buffer (shown as conductivity) has no significant influence on the amount of residual HCP eluting from the cation exchange resin (Toyopearl GigaCap CM-650M, see Figure 2). With increasing pH of the binding buffer up to neutral pH values, an increased influence of the ionic strength on the HCP removal can be observed. Similar high throughput screening experiments were performed for anion exchange and hydrophobic interaction chromatography (data not shown). By applying the ideal conditions for each unit operation, various downstream process platform strategies can be simulated easily at lab scale.
Figure 3: Pressure flow characteristics of polymethacrylate-based process resins. Rigid, polymeric process resins can be used at high flow rates. Toyopearl GigaCap S-650M cation exchange resin with a mean particle size of 75 μm (grey), as well as Toyopearl AF-rProtein A-650F (red) with a mean particle size of 45 μm can be used at linear velocities of more than 1,000 cm/hr.
Future challenges of mAb purification will be provided by the further increase in cell culture titres. Chromatographic operations thus become limited in terms of the throughput they can provide. The ability to run a chromatographic purification step at a broad range of velocities and sample loads expands the design space provided by a validated purification platform. The use of resins providing a high mechanical stability and maintaining high protein binding capacities at high velocities supports these requests.
Regina Römling is Marketing Manager at Tosoh Bioscience GmbH, with responsibility for the marketing of separation products such as HPLC columns and process resins. Prior to joining the Tosoh team in 2007, she was a Product Specialist for HPLC systems at Shimadzu. In 1990, Regina graduated in chemistry, specialising in biochemistry, at the Westfälische Wilhelms-University of Münster (Germany). Her background includes five years of research work in molecular biology and genetic engineering at the University Hospital, Münster, and about 15 years’ experience in liquid chromatography and mass spectrometry.
Egbert Müller is Technical Director at Tosoh Bioscience GmbH. He has a PhD in Theoretical Chemistry and a Habilitation in Bioseparation, is a Lecturer in Industrial Biotechnology at the University of Darmstadt (Germany), and is a Group Leader for research grant projects that receive funding from the Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research) in Germany. Egbert serves on the Scientific Advisory Board of the International Symposium on the Separation of Proteins, Peptides & Polynucleotides (ISPPP), and is a member of the Society for Affinity and Molecular Recognition. He is owner of more than 30 patents for surface modification techniques of chromatographic resins.
A new application notebook contains many examples for GPC/SEC analysis for a broad range of polymers more
As demonstrated here, there are a broad range of HPLC applications used in development, production, validation and release of protein therapeutics for human use. Some of the applications mentioned above are mandatory when submitting a new biopharmace more
One of the most widely used water-soluble polymers is Polyvinylpyrrolidone (PVP). For more than 70 years it is applied in a variety of applications in medicine, pharmacy, cosmetics and industrial production. PVP binds to polar molecules exceptionally more
Tosoh's EcoSEC GPC systems for room or high temperature polymer analysis operate 50% faster than many other GPC systems. more
20 years ago, on July 20, 1989, TosoHaas opened the doors to the Biopharmaceutical industry. Starting out with a team of five employees, TosoHaas, over time, developed into a profitable business with constant growth. In the start TosoHaas focused on promoting the nowadays well known TSK-GE ... more
Research and Markets has announced the addition of the "Ethylene Market Outlook 2008" report to their offering. The report analyzes worldwide markets for Ethylene, including Europe, Asia, North America, Latin America, Middle East and Africa, Oceania. It provides the most complete and curre ... more
Tosoh Corporation announced that it will raise its stake in Nippon Polyurethane Industry Co. Ltd. (NPU) to 51% from the current 35% by acquiring NPU shares held by affiliate, Hodogaya Chemical Co. Ltd. The move further accelerates Tosoh's vinyl-isocyanate strategy and strengthens ties as th ... more
Tosoh Bioscience is an acknowledged global leader in the field of liquid chromatography with a focus on bioseparations. For more than 25 years, Tosoh Bioscience is providing cutting-edge solutions for customers developing and producing biologics, biosimilars or biobetters. The product portf ... more
TOSOH Europe B.V. is a regional head office for Tosoh Corporation and serves as the European sales, marketing, and business development center. The Company is proud to provide innovative products with reliable service that customers can depend on. As part of Tosoh Corporation’s overall stra ... more